← Leaderboards
Priscilla Li-Ning Yang
Harvard Medical School
$20,185,658
Attributed
$25,184,275
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2008–24$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$25,184,275 · 13
By mechanism
R01$12,134,375 · 4
U19$10,667,772 · 2
R21$1,530,437 · 4
U54$459,196 · 2
R56$392,495 · 1
Top collaborators
- Nathanael Schiander Gray14 shared
Most similar at Harvard Medical School
Same institution · by research overlap
- Ritchie Edward Brown$1,198,851
- Adam Johnson$59,038
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusViralAntiviral AgentsPharmaceutical PreparationsResistanceSmall MoleculeIn VitroDengue VirusCellsProteinsAffectIn VivoMutationDesignMediatingSerotypingMutantVaccinesInfectionInhibitor/AntagonistLeadSeriesVirionVirus Replication
Grant awards (38)
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2024 · AI · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$835,944
R01 · FY2024 · AI · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2023 · AI · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$835,944
R01 · FY2023 · AI · contact PI
Small molecule inhibitors and degraders of picornavirus 2A proteases as direct-acting antivirals$3,728,844
U19 · FY2022 · AI · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2022 · AI · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$810,874
R01 · FY2022 · AI · contact PI
Small molecule degraders of HIV-1 Nef$236,100
R21 · FY2022 · AI · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$851,884
R01 · FY2021 · AI · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$811,132
R01 · FY2021 · AI · contact PI
How Hepatitis C Virus Regulates Desmosterol to Affect RNA Replication: a New Virus-Host Interaction$236,190
R21 · FY2021 · AI · contact PI
Small molecule degraders of HIV-1 Nef$187,048
R21 · FY2021 · AI · contact PI
Small molecule degraders of HIV-1 Nef$24,202
R21 · FY2021 · AI · contact PI
How Hepatitis C Virus Regulates Desmosterol to Affect RNA Replication: a New Virus-Host Interaction$1
R21 · FY2021 · AI · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$833,361
R01 · FY2020 · AI · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$829,756
R01 · FY2020 · AI · contact PI
How Hepatitis C Virus Regulates Desmosterol to Affect RNA Replication: a New Virus-Host Interaction$211,875
R21 · FY2020 · AI · contact PI
Small-molecule inhibitors of flavivirus entry$1,424,274
U19 · FY2018 · AI · contact PI
Small-molecule inhibitors of flavivirus entry$1,504,859
U19 · FY2017 · AI · contact PI
Small-molecule inhibitors of flavivirus entry$1,739,831
U19 · FY2016 · AI · contact PI
Chemical Tools for the Study of Dengue Virus Entry$349,821
R01 · FY2016 · AI · contact PI
Small-molecule inhibitors of flavivirus entry$1,128,723
U19 · FY2015 · AI · contact PI
Chemical Tools for the Study of Dengue Virus Entry$509,576
R01 · FY2015 · AI · contact PI
Small-molecule inhibitors of flavivirus entry$1,141,241
U19 · FY2014 · AI · contact PI
Chemical Tools for the Study of Dengue Virus Entry$421,606
R01 · FY2014 · AI · contact PI
Chemical Tools for the Study of Dengue Virus Entry$23,730
R01 · FY2014 · AI · contact PI
Disubstituted pyrimidine inhibitors of dengue virus entry$210,785
U54 · FY2013 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$458,407
R01 · FY2012 · AI · contact PI
Disubstituted pyrimidine inhibitors of dengue virus entry$248,411
U54 · FY2012 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$460,358
R01 · FY2011 · AI · contact PI
Chemical Tools for the Study of Dengue Virus Entry$392,495
R56 · FY2011 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$373,254
R01 · FY2010 · AI · contact PI
Directed Evolution of a Murine Model of Hepatitis C Virus Replication$254,250
R21 · FY2010 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$91,884
R01 · FY2010 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$377,060
R01 · FY2009 · AI · contact PI
Directed Evolution of a Murine Model of Hepatitis C Virus Replication$211,771
R21 · FY2009 · AI · contact PI
Validation of Src kinases as Anti-Dengue Viral Targets$376,178
R01 · FY2008 · AI · contact PI
Development of Cellular Assays of Dengue Virus Infection$169,000
R21 · FY2008 · NS · contact PI